Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

Non-hodgkin's Lymphoma Clinical Trial

— PRISM  

Official title:

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03527147
• Other study ID #: ACE-LY-111
• Secondary ID: 2017-004191-63D9
• Status: Completed
• Phase: Phase 1
• Start date: June 19, 2018
• Est. completion date: March 31, 2021

Study information

• Verified date: August 2022
• Source: Acerta Pharma BV
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL).

Description:

This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's lymphoma (NHL). Each study arm will be conducted in a predefined disease subset. All study arms are open label and allocation to each study arm will not be randomized.

As this master platform protocol has multiple study arms, subjects can be screened for several study arms at once. Likewise, a subject who ends participation in one study arm may be rescreened for participation in another (separate) study arm.

The primary objective of the study is to evaluate the safety of targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL). This protocol has a modular design, with the potential for future treatment arms to be added via protocol amendment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: March 31, 2021
• Est. primary completion date: March 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 130 Years

Eligibility

Inclusion Criteria:

Inclusion Criteria For All Arms:

1. Diagnosis of relapsed/refractory aggressive Non Hodgkin's Lymphoma (NHL) with histology based on established World Health Organization (WHO) criteria.

2. Must have received =1 prior line of therapy for the treatment of current histology, there are no known curative treatment options available, or subject ineligible for potential curative options.

3. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy. Not applicable for cutaneous lesions.

4. ECOG performance status of =2.

Inclusion Criteria for Arm 1:

1. Must have previously received rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone or equivalent regimen with stem-cell rescue. Or who are ineligible for highdose chemotherapy with stem-cell rescue and/or chimeric antigen receptor (CAR) T cell therapy.

Ineligibility for high-dose therapy with stem cell rescue and/or CAR T-cell therapy will be determined by the investigator.

Inclusion Criteria for Arm 2:

1. Must have previously received rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone or equivalent regimen with stem-cell rescue. Or who are ineligible for highdose chemotherapy with stem-cell rescue and/or chimeric antigen receptor (CAR) T-cell therapy.

Ineligibility for high-dose therapy with stem cell rescue and/or CAR T-cell therapy will be determined by the investigator.

Inclusion Criteria for Arm 3:

1. Must have previously received rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone or equivalent regimen with stem-cell rescue. Or who are ineligible for highdose chemotherapy with stem-cell rescue and/or chimeric antigen receptor (CAR) T cell therapy.

Ineligibility for high-dose therapy with stem cell rescue and/or CAR T-cell therapy will be determined by the investigator.

Inclusion Criteria for Arm 4:

1. Must have previously received rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone or equivalent regimen with stem-cell rescue. Or who are ineligible for highdose chemotherapy with stem-cell rescue and/or chimeric antigen receptor (CAR) T cell therapy.

Ineligibility for high-dose therapy with stem cell rescue and/or CAR T-cell therapy will be determined by the investigator.

Exclusion Criteria:

Exclusion Criteria For All Arms:

1. History of prior malignancy except for the following: a) Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening and felt to be at low risk for recurrence by treating physician, b) Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled nonmelanomatous skin cancer, c) Adequately treated carcinoma in situ without current evidence of disease, d) Evidence of severe or uncontrolled systemic disease, or current unstable or uncompensated respiratory or cardiac conditions, or uncontrolled hypertension, history of, or active, bleeding diatheses or uncontrolled active systemic fungal, bacterial, viral, or other infection, or intravenous anti-infective treatment within 2 weeks before first dose of study treatment.

2. Serologic status reflecting active hepatitis B or C infection.

3. Prior use of standard antilymphoma therapy or radiation therapy within 14 days of receiving the first dose of study treatment (not including palliative radiotherapy or palliative corticosteroid use).

4. Requires ongoing immunosuppressive therapy, including systemic corticosteroids for treatment of lymphoid cancer or other conditions.

5. For subjects under DLT review only: Any haematopoietic growth factors or darbepoetin within 14 days of the first dose of study treatment.

Exclusion Criteria for Arm 1:

1. Presence of central nervous system (CNS) lymphoma or leptomeningeal disease.

2. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.

3. Requires treatment with proton-pump inhibitors.

4. Requires treatment with strong CYP3A inhibitors or inducers.

Exclusion Criteria for Arm 2:

1. Relative hypotension (< 90/60 mm Hg) or clinically relevant orthostatic hypotension, including a fall in blood pressure of >20 mm Hg.

2. Uncontrolled hypertension requiring clinical intervention.

3. At risk for brain perfusion problems based on medical history.

4. Mean resting QT interval (QTc) calculated using Fridericia's formula (QTcF) >470 msec for female subjects and >450 msec for male subjects obtained from 3 electrocardiograms (ECGs), or congenital long QT syndrome.

5. Presence of central nervous system (CNS) lymphoma or leptomeningeal disease.

6. Known to have tested positive for human immunodeficiency virus (HIV) & requires treatment with restricted medications.

7. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.

8. Requires treatment with proton-pump inhibitors.

Exclusion Criteria for Arm 3:

1. Presence of central nervous system (CNS) lymphoma or leptomeningeal disease.

2. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.

3. Requires treatment with proton-pump inhibitors.

4. Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 units of RBC transfusions during the 4-week period prior to screening.

5. History of haemolytic anaemia or Evans syndrome in the last 3 months before enrolment.

6. Positive IgG component of the direct antiglobulin test (DAT).

7. Prior treatment with CD47 or SIRPa-targeting agents.

8. Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients of rituximab

Exclusion Criteria for Arm 4:

1. Presence of central nervous system (CNS) lymphoma or leptomeningeal disease.

2. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.

3. Requires treatment with proton-pump inhibitors.

4. Requires treatment with CYP3A inhibitors or inducers or substrates of drug transporters.

5. History of tuberculosis.

6. Mean resting corrected QT interval (QTcF) >450 msec obtained from 3 electrocardiograms (ECGs); clinically important ECG findings, or risk factors for QTc prolongation.

7. Subjects receiving antiplatelet or anticoagulant therapies within 28 days of first dose of study drug.

Related Conditions & MeSH terms

• Diffuse Large B Cell Lymphoma
• DLBCL
• Lymphoma
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Non-Hodgkin
• NHL
• Non-hodgkin's Lymphoma

Intervention

Drug:
• AZD9150
AZD9150 will be administered as a 1-hour intravenous (IV) infusion on Days 1, 3, 5 of Cycle 1, followed by weekly infusions (starting Day 8 of Cycle 1 and beyond).
• Acalabrutinib
Acalabrutinib will be administered orally twice daily (bid).
• AZD6738
AZD6738 will be administered orally twice daily (bid).
• Hu5F9-G4
HU5F9-G4 infusions will be given on Weekly (Day 1, 8, 15, and 22) during the first two 28-day cycles, then will be given every two weeks (Day 1 and Day 15) in Cycle 3 and beyond.
• Rituximab
Rituximab infusions will be given Weekly starting on Day 8 (Day 8, 15, and 22) during the first 28-day cycle (4 weeks), then Day 1 of each 4 week cycle for Cycles 2-6. Starting with Cycle 8, Rituximab will be infused on Day 1 of every other cycle (every 8 weeks).
• AZD5153
AZD5153 will be administered orally once per day (qd).

Locations

Country	Name	City	State
United Kingdom	Research Site	London
United Kingdom	Research Site	Oxford
United States	Research Site	Atlanta	Georgia
United States	Research Site	Bethesda	Maryland
United States	Research Site	Charlottesville	Virginia
United States	Research Site	Los Angeles	California
United States	Research Site	Nashville	Tennessee
United States	Research Site	New Orleans	Louisiana
United States	Research Site	Omaha	Nebraska
United States	Research Site	Rochester	New York
United States	Research Site	Sarasota	Florida
United States	Research Site	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Acerta Pharma BV	AstraZeneca

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of the study treatments when given in combination [Incidence of adverse events]	Incidence of adverse events	Through to study completion, an average of 1 year
Secondary	Assessment of the efficacy of each treatment by evaluation of overall response rate using RECIL 2017 response criteria	The overall response rate (ORR) is defined as the rate of subjects who achieve either a partial response (PR) or complete response (CR) as assessed by investigators before receiving any other anticancer therapy.	Through to study completion, an average of 1 year
Secondary	Duration of response (DOR) using RECIL 2017 response criteria for the anti-tumour activity of each therapy.	Duration of Response (DOR) is defined as the time from the first objective response of CR or PR to the time of documented disease progression or death due to any cause, whichever occurs first.	Through to study completion, an average of 1 year
Secondary	Progression free survival (PFS) using RECIL 2017 response criteria for the anti-tumour activity of each therapy.	Progression free survival (PFS) is defined as the time from first dose date to documented objective disease progression, or death from any cause, whichever occurs first. Disease progression will be determined by the investigators per standard response criteria as outlined in each respective study arm.	Through to study completion, an average of 1 year
Secondary	Overall Survival (OS)	Overall Survival (OS) is defined as the time from first dose until the date of death from any cause.	From the beginning of treatment until the date of death from any cause, assessed up to 12 months
Secondary	Peak plasma concentration (Cmax) of Study Drug A (Arm 1)		Samples will be collected predose and 1, 4, 6 hours postdose on Cycle 1 Day 8 only; then predose and approximately 1 hr (end of infusion of Study Drug A) on Day 1 of every odd cycle starting with Cycle 3 through study completion, an average of 1 year
Secondary	Peak plasma concentration (Cmax) of Study Drug B (Arm 2)		Samples will be collected predose and 1, 4, 8 hours postdose on Cycle 1 Day 8 only; then predose on Cycle 2 Day 1 and Cycle 3 Day 1
Secondary	Area under the plasma concentration versus time curve (AUC) of Study Drug A (Arm 1)		Samples will be collected predose and 1, 4, 6 hours postdose on Cycle 1 Day 8 only; then predose and approximately 1 hr (end of infusion of Study Drug A) on Day 1 of every odd cycle starting with Cycle 3 through study completion, an average of 1 year
Secondary	Area under the plasma concentration versus time curve (AUC) of Study Drug B (Arm 2)		Samples will be collected predose and 1, 4, 8 hours postdose on Cycle 1 Day 8 only; then predose on Cycle 2 Day 1 and Cycle 3 Day 1
Secondary	Presence of Anti-Drug Antibody (ADA) titres in subjects treated with Study Drug A		Samples will be collected predose on Days 1 and 8 of Cycle 1 and predose on Day 1 of every odd cycle starting with Cycle 3
Secondary	Peak plasma concentration (Cmax) of acalabrutinib (Arm 1)		Samples will be collected predose and 1, 4, 6 hours postdose on Cycle 1 Day 8 only
Secondary	Area under the plasma concentration versus time curve (AUC) for acalabrutinib (Arm 1)		Samples will be collected predose and 1, 4, 6 hours postdose on Cycle 1 Day 8 only
Secondary	Peak plasma concentration (Cmax) of acalabrutinib (Arm 2)		Samples will be collected predose and 1, 4, 8 hours postdose on Cycle 1 Day 8 only; then predose on Cycle 2 Day 1 and Cycle 3 Day 1
Secondary	Area under the plasma concentration versus time curve (AUC) for acalabrutinib (Arm 2)		Samples will be collected predose and 1, 4, 8 hours postdose on Cycle 1 Day 8 only; then predose on Cycle 2 Day 1 and Cycle 3 Day 1

External Links

•   Related Info
•   Results of this clinical trial are available on www.astrazenecaclinicaltrials.com